knowledge -WSS

knowledge

author：leisure time 2025-09-27 16:23:09 - browse：6

Kidney transplants are the most common organ transplant procedure in the U.S., with 25,000 taking place in 2022. But for patients who receive new kidneys, the transplant is often followed by severe lifelong challenges, many of which are linked to the immunosuppression drug regimen required after surgery to ensure the body does not reject the new organ. These treatments have side effects and toxicities that impact patients’ long-term health, and even survival, leading to a transplant failure rate of 30-50% at the 10-year mark.

Now a new trial sponsored by Medeor Therapeutics, the results of which were presented Thursday at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting, offers hope that stem cell therapy may help patients discontinue their immunosuppressant regime within a year of the transplant.

“The ability to get a transplant without being on lifelong immunosuppression is kind of a dream in transplant, so I can see why this would generate a lot of excitement,” said Sommer Gentry, a professor of surgery at New York University, who was not involved in the study and was not at the actual presentation, but reviewed the trial’s presentation slides.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

hotspot

WSS

Videos point to link between seizures and unexplained toddler deaths

Chemotherapy before breast cancer surgery might fuel metastasis

The creative science of coining drug names

Has Bernie Sanders reached the limit of his pharma bullying effort?

Deliver public health messages at the right time

Can gargling with Listerine treat gonorrhea of the mouth?

leisure time

knowledge

entertainment

Medical records are filled with copy

Morgan Health, with ambitious aims, wants you to know it’s still here

Duchenne breakthrough therapy leaves behind pioneering families

U.K. sequencing study surfaces new findings about tumor DNA

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

After affirmative action ruling, medical educators look to 'holistic review'

3 medical device trends to watch in 2024

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Videos point to link between seizures and unexplained toddler deaths

focus

HHS's proposed rule does nothing to address the climate crisis

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

How a scoliosis diagnosis changed the life of one young dancer

AltruBio raises $225 million to develop ulcerative colitis drug

A single drug, study failures leave Anavex with nothing but cash

UCB departs biotech trade group BIO

hotspot

Wikipedia

hotspot

hotspot